Literature DB >> 32533051

Trastuzumab deruxtecan improves survival.

Peter Sidaway1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32533051     DOI： 10.1038/s41571-020-0406-y

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.

Authors:  Kohei Shitara; Yung-Jue Bang; Satoru Iwasa; Naotoshi Sugimoto; Min-Hee Ryu; Daisuke Sakai; Hyun-Cheol Chung; Hisato Kawakami; Hiroshi Yabusaki; Jeeyun Lee; Kaku Saito; Yoshinori Kawaguchi; Takahiro Kamio; Akihito Kojima; Masahiro Sugihara; Kensei Yamaguchi
Journal:  N Engl J Med       Date:  2020-05-29       Impact factor: 91.245
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.